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ABSTRACT: We conducted a systematic review and meta-analysis to assess the evidence for the
postulation that inappropriate tuberculosis (TB) regimens are a risk for development of multidrug-
resistant (MDR)-TB.
MEDLINE, EMBASE and other databases were searched for relevant articles in January 2011.
Cohort studies including TB patients who received treatment were selected and data on treatment
regimen, drug susceptibility testing results and genotyping results before treatment and at failure
or relapse were abstracted from the articles.
Four studies were included in the systematic review and two were included in the meta-analysis.
In these two studies the risk of developing MDR-TB in patients who failed treatment and used an
inappropriate treatment regimen was increased 27-fold (RR 26.7, 95% CI 5.0–141.7) when
compared with individuals who received an appropriate treatment regimen.
This review provides evidence that supports the general opinion that the development of MDR-
TB can be caused by inadequate treatment, given the drug susceptibility pattern of the
Mycobacterium tuberculosis bacilli. It should be noted that only two studies provided data for the
meta-analysis. The information can be used to advocate for adequate treatment for patients based
on drug resistance profiles.
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M
ultidrug resistance remains a threat to
tuberculosis (TB) control [1]. It is gen-
erally accepted that the development of
drug resistance and multidrug-resistant (MDR)-
TB is caused by inadequate treatment, i.e. regi-
mens with an inadequate number of drugs to
which the bacilli are susceptible, an inadequate
dose or dosing frequency, an inadequate quality
of the drugs, or an inadequate adherence to the
regimen. The aim of this review was to assess the
evidence for this hypothesis. As new anti-TB
drugs become available, it is important to assess
the best process for their introduction and use in
TB regimens at an early stage. If the hypothesis
holds, it will add to and strengthen the evidence
that the introduction of new TB drugs, in TB
treatment regimens, needs to be performed with
great care to prevent the development of resis-
tance against new TB drugs.
Assessing whether drug resistance develops when
inadequate treatment is provided requires studies
that provide information on: drug susceptibility
testing (DST) before the start of treatment, the
treatment regimen undertaken by each individual
in the study, DST of specimens obtained from
individuals that fail treatment or relapse, and
genotyping information of the initial strain (col-
lected before treatment) and of the strain that is
present at failure or relapse.
Data from low- and high-prevalence areas show
that patients can be re-infected with a new strain
of TB during treatment or after successful
treatment [2, 3]. Since patients might be re-
infected with a resistant strain, ‘‘acquired’’ drug
resistance can only be diagnosed if the possibility
of re-infection is excluded. Re-infection can only
be excluded by genotyping the strain that caused
AFFILIATIONS
*KNCV Tuberculosis Foundation, The
Hague, and
#Center for Infection and Immunity
Amsterdam (CINIMA), and
"Dutch Cochrane Centre, Academic
Medical Center, University of
Amsterdam, Amsterdam, The
Netherlands.
+European Centre for Disease
Prevention and Control (ECDC),
Stockholm, Sweden.
CORRESPONDENCE
M.J. van der Werf
European Centre for Disease
Prevention and Control (ECDC)
SE-171 83 Stockholm
Sweden
E-mail: Marieke.vanderwerf@
ecdc.europa.eu
Received:
July 22 2011
Accepted after revision:
Sept 21 2011
First published online:
Oct 17 2011
European Respiratory Journal
Print ISSN 0903-1936
Online ISSN 1399-3003
Previous articles in this series: No. 1: Langendam MW, van der Werf MJ, Huitric E, et al. Prevalence of inappropriate tuberculosis treatment regimens: a
systematic review. Eur Respir J 2012; 39: 1012–1020. No. 2: van der Werf MJ, Langendam MW, Huitric E, et al. Knowledge of tuberculosis-treatment prescription
of health workers: a systematic review. Eur Respir J 2012; 39: 1248–1255.
EUROPEAN RESPIRATORY JOURNAL VOLUME 39 NUMBER 6 1511
Eur Respir J 2012; 39: 1511–1519
DOI: 10.1183/09031936.00125711
CopyrightERS 2012
ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Licence 3.0
cthe initial episode and the strain that is present in the sample
taken at failure or recurrence. The method most frequently used
to collect information about the genotype is restriction fragment
length polymorphism (RFLP) analysis [4]. VAN EMBDEN et al. [4]
first proposed this standard methodology for strain identifica-
tion in 1993. Other methods include variable number of tandem
repeats typing [5] or spoligotyping [6].
We conducted a systematic review and meta-analysis accord-
ing to the Cochrane Handbook for Systematic Reviews and the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement [7, 8] to assess the risk for
development of MDR-TB after the use of inappropriate TB
regimens.
METHODS
Search strategy
To identify relevant studies we conducted a literature search in
the bibliographic databases MEDLINE and EMBASE in January
2011. We searched for guidelines in the National Guideline
Clearinghouse, and the National Institute for Clinical Excellence
(NICE) and Scottish Intercollegiate Guidelines Network (SIGN)
databases. In addition abstracts of conference proceedings were
sought in the research database BIOSIS. Reviews and guidelines
were searched for in the TRIP database. The World Health
Organization (WHO) International Clinical Trials Registry
Platform (ICTRP) was evaluated for ongoing trials that might
provide relevant data. Key words used in the search were
determined in collaboration with the clinical librarian of the
Dutch Cochrane Centre (Amsterdam, the Netherlands) and
included ‘‘Tuberculosis’’ OR ‘‘TB’’ OR ‘‘Mycobacterium’’ AND
for TB treatment ‘‘Prescriptions’’ OR ‘‘Treatment regimen’’ OR
‘‘Combination treatment’’ OR ‘‘Treatment strategy/-ies’’ OR
‘‘Drug supply’’ OR ‘‘Standard treatment/standard regimen’’
OR ‘‘Inappropiate use, appropriate use, rational use, irrational
use, misuse’’ AND for drug resistance ‘‘drug or multidrug’’ OR
‘‘extensive or extensively’’ OR ‘‘drug and resistance or resis-
tant’’. We excluded case reports. The search strategy was
supplemented by hand searching reference lists of identified
articles and relevant review articles.
Selection of studies and quality assessment
We initially planned to include cohort studies investigating
the use of inappropriate TB regimens as a risk factor for the
development of drug resistance. However, none of the cohort
studies, identified in the search, investigated the use of
inappropriate TB regimens as a risk factor for the develop-
ment of drug resistance. Therefore, we widened our selection
and inclusion criteria to cohort studies that provided treat-
ment to non-MDR-TB patients and measured drug resistance
and genotype of the isolated Mycobacterium tuberculosis bacilli
before treatment started, and drug resistance and genotype in
failure and/or recurrent TB cases. Only studies that included
TB patients meeting either the WHO definitions for ‘‘definite
case’’ [9], or meeting the ‘‘possible’’, ‘‘probable’’ or ‘‘definite’’
case definition as published by the European Commission in
2008 [10] were included. Articles published in Dutch, English,
French, German, Italian, Portuguese, Spanish or Swedish were
included.
Studies identified by the search strategy were reviewed for
eligibility based on title and abstract by one investigator
(M.J. van der Werf). If it could not be assessed with certainty
whether there was reason for exclusion of a record the record
was kept for the second selection step. Full manuscripts of
the records kept based on title/abstract were assessed by
one investigator (M.J. van der Werf). For both steps, a 10%
random sample was assessed by a second investigator
(M.W. Langendam) and compared with the assessment of
the first reviewer. Inconsistencies in assessment were dis-
cussed and disagreements resolved by consensus. A complete
double selection was planned if the 10% random sample
assessment revealed relevant inconsistencies.
Data extraction
One reviewer (M.J. van der Werf) extracted all relevant data
items from the included studies using a data extraction form. A
second reviewer (M.W. Langendam) independently extracted
the main results of the included studies and checked the other
extracted results for a subsample of the articles. Inconsistencies
were discussed to obtain consensus. The risk of bias of the
individual studies was assessed by two reviewers indepen-
dently using the Newcastle–Ottawa Scale (NOS) [11].
Data analysis and synthesis of results
For studies that were clinically and methodologically homo-
geneous, a meta-analysis was performed using Review
Manager software version 5.0 (Copenhagen, The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008). For other
studies, the results were summarised qualitatively. If results
were missing in a study (e.g. due to contamination of culture or
because the sample was not collected) attempts were made to
extrapolate the missing information from the information
provided in the article or by contacting the authors.
For the analysis, appropriate treatment regimens were defined
for TB patients with different drug resistance patterns. The
WHO TB treatment guidelines were a source for defining the
number and type of effective drugs required for the initial
treatment phase and for the continuation phase (table 1)
[ 9 ,1 2 ] .T r e a t m e n tr e g i m e n sw e re considered appropriate if
the patient had disease due to a pansusceptible strain and
the regimen contained isoniazid and rifampicin and two
other drugs in the intensive phase, and isoniazid and
rifampicin in the continuation phase. If the patient had
disease caused by a strain monoresistant to isoniazid the
intensive phase needed to contain isoniazid and rifampicin
and two other drugs. The continuation phase included
isoniazid, rifampicin and ethambutol. Patients with non-
MDR-TB that were susceptible to rifampicin needed a
r e g i m e nw i t ha tl e a s tt h r e ed rugs to which the strain is
susceptible in both phases and patients with non-MDR-TB
and resistance to rifampicin needed a regimen that included
at least four drugs to which the strain was susceptible. All
other regimens were con-
sidered inappropriate.
Definitions of MDR-TB, acquired MDR-TB, recurrence, relapse
and re-infection are provided in table 2 [9, 13]. In this study,
acquired MDR-TB was defined as a case with an initial strain
susceptible to at least isoniazid or rifampicin, which was then
MDR-TB at the time of failure or disease recurrence and with a
genotype pattern identical to the initial strain at the time of first
diagnosis.
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Recommendations Assessment, Development and Evaluation
(GRADE) approach [14].
RESULTS
Study selection
Of the 701 records identified from the MEDLINE and EMBASE
searches, 81 were kept for evaluation of the full manuscript. Of
these records, two studies fulfilled the eligibility criteria [15, 16].
Figure 1 shows why records were excluded based on the
assessment of title/abstract and full manuscripts. Three
relevant reviews were identified in the MEDLINE and
EMBASE search [17–19].
The National Guideline Clearinghouse, NICE, SIGN, and
BIOSIS databases did not provide relevant aggregated evi-
dence. The WHO ICTRP did not include ongoing trials that
might provide relevant data. The TRIP database provided 212
systematic reviews and 220 guidelines for the search terms
‘‘Tuberculosis’’ and ‘‘Treatment’’. Two additional systematic
reviews were considered relevant [20, 21]. Checking the
reference lists of the identified reviews provided five poten-
tially relevant primary studies [22–26]. None of the studies
could be included as it was not possible to link individual
treatment information with DST and genotyping information
or the treatment regimen was not mentioned in sufficient
detail.
Hand searching reference listsofidentifiedarticlesprovided two
additional papers that fulfilled the eligibility criteria [27, 28].
Description of the included studies
All four included studies were cohort studies (tables 3 and 4).
They included 233–2,901 TB patients at the start of treatment
who were followed up until the end of treatment to identify
failure cases [15, 27], or followed up for .1.5–3 yrs after
treatment to identify cases that had recurrent TB [16, 28].
The included studies did not provide sufficient detailed
information about dose or dosing frequency, quality of the
drugs, or adherence to the regimen to assess the association of
these factors with the development of MDR-TB.
SONNENBERG et al. [28] included TB patients with an episode of
TB that was proven by culture. QUY et al. [16] included new
smear-positive TB patients (either two sputum smears with
acid-fast bacilli or one positive smear and an abnormal chest
radiograph consistent with TB). COX et al. [27] included smear-
positive pulmonary TB patients (at least one sputum sample
reading .10 bacilli/100 fields in a sputum smear by direct
microscopy). MATTHYS et al. [15] included patients diagnosed
with TB through sputum smear and culture. All included
patients fulfilled the definition of a definite TB case according
to the WHO definition [9] and the definition of the European
Commission [10].
Risk of bias assessment
Table 5 presents the results of the risk of bias assessment of the
four studies using the star template. The three studies that
scored four stars for selection all included a sample of the
general population [16, 27, 28]. However, none of these three
studies were considered truly representative of the average
population at risk for acquiring MDR-TB. The fourth study
was in a selected group, prisoners with TB who were admitted
to a referral penitentiary hospital and was, therefore, con-
sidered not representative of the general population [15]. In all
four studies, the unexposed cohort (those who received an
appropriate TB regimen) was drawn from the same commu-
nity as the exposed cohort, so there was minimal risk of bias in
the selection of the unexposed. Also, all four studies measured
exposure (receiving an inappropriate TB regimen) with
sufficient quality. We only selected studies that performed
DST before treatment so the outcome of interest (MDR-TB) was
not present at the start of the study. None of the four included
studies assessed differences between individuals receiving
appropriate treatment and inappropriate treatment, so an
assessment of the comparability of the exposed and unexposed
cohort was not performed.
As mentioned in the Methods section, the included studies
were not designed to investigate the use of inappropriate TB
regimens as a risk factor for drug resistance. Thus, the
assessment of outcome was not influenced, because the
authors did not look separately at the group of exposed and
unexposed TB patients. We considered a follow-up until the
TABLE 1 Appropriate treatment regimens for tuberculosis
(TB) patients with strains that have certain drug
resistance patterns
Drug resistance
pattern
Appropriate treatment regimen
Pansusceptible HR and two other drugs in intensive phase and HR
in the continuation phase
H HR and two other drugs in intensive phase and HRE
in the continuation phase
#
Non-MDR-TB,
R susceptible
At least three drugs to which the strain is sensitive
in the intensive and continuation phase
"
Non-MDR-TB,
R resistant
At least four drugs to which the strain is sensitive
in the intensive and continuation phase
"
H: isoniazid; MDR: multidrug resistant; R: Rifampicin; E: Ethambutol.
#: based
on [9].
": based on [12].
TABLE 2 Definitions of multidrug-resistant (MDR)-
tuberculosis (TB), acquired MDR-TB, recurrence,
relapse and re-infection
Definition
MDR-TB TB resistant to at least isoniazid and rifampicin.
Acquired
MDR-TB
A case with an initial strain susceptible to at least
isoniazid or rifampicin that developed MDR-TB
and has a genotyping pattern identical to the strain
at time of diagnosis.
Recurrence A second episode of TB occurring after a first episode
has been considered cured.
Relapse A second episode of TB occurring after a first
episode has been considered cured with the same
Mycobacterium tuberculosis strain as the first episode.
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follow-up of a minimum of 1 yr for the identification of
recurrence cases. In all four studies the follow-up was long
enough for the outcome to occur.
In conclusion, study quality was moderate to high. Two
studies provided data for acquired MDR-TB in failure cases
[15, 27]. One study provided data for acquired MDR-TB in
recurrence cases [28] and QUY et al. [16] provided information
for acquired MDR-TB in both failure and recurrence cases.
Meta-analysis
All TB patients in the study by QUY et al. [16] received
inappropriate treatment, as the continuation phase consisted of
isoniazid and ethambutol and not isoniazid and rifampicin
(table 6). QUYet al. [16] showed that the risk of acquiring MDR-
TB was 1.5% for failure cases and 0.4% for recurrence cases,
after correction for missing culture results. The study by
SONNENBERG et al. [28] had both patients who received an
appropriate TB regimen and patients who received an
inappropriate TB regimen. However, this study did not have
any events; i.e. none of the patients presenting with MDR-TB at
recurrence had a strain with an identical genotype pattern to
the initial strain at the time of diagnosis. As these two studies
did not have both exposed and unexposed individuals and
events, they could not be included in the meta-analysis and
thus only two of the four studies were available for meta-
analysis [15, 27].
We used a fixed-effects model for the meta-analysis due to the
low number of studies. Patients who received an inappropri-
ate treatment regimen had a 27-fold increased risk of
developing MDR-TB (RR 26.7, 95% CI 5.0–141.7) (fig. 2). For
two patients it was not clear whether they had acquired MDR-
TB or whether they were re-infected with an MDR strain.
One of these patients was a patient who had MDR-TB at
recurrence [27] and the other was diagnosed with MDR-TB at
failure [15]. For the main analysis we included these two cases
as re-infection cases and they were not counted as events.
Including these two cases as acquired MDR-TB cases in the
meta-analysis results in a slightly lower risk ratio (RR 17.7,
95% CI 4.1–77.6).
Using the GRADE approach we started with low quality
evidence as we included observational studies. There was no
need to downgrade the quality of the evidence due to study
Identified from MEDLINE, EMBASE
and other databases (after
eliminating duplicates): 701 records
620 records excluded based on
title and abstract:
  110 not about TB
  8 about latent TB
  297 no observational study
  58 only MDR-TB patients included
  13 no treatment provided
  60 no DST after treatment
  74 cross-sectional drug resistance
  survey
Records retained for review of
full manuscript: 81
Records included: 2
79 records excluded based on
evaluation of full manuscript:
  6 language
  18 no cohort study
  23 treatment regimen is not
  reported for individual patients
  26 drug resistance information not
  available before treatment and at
  failure or relapse
  6 genotyping information not
  available before treatment and at
  failure or relapse
FIGURE 1. Summary of literature search and study selection. TB: tuberculosis;
MDR: multidrug resistant; DST: drug susceptibility testing.
TABLE 3 General characteristics of the study populations
First author [ref.] Age in median yrs or n (%) Male % HIV positive % Type of TB Prior TB treatment %
SONNENBERG [28] ,30: 35 (10.7) Not reported 46.3 Culture-positive TB patients without
multidrug resistance and cured of TB
22.7
30–39: 163 (50.0)
40–49: 84 (25.8)
o50: 44 (13.5)
QUY [16] 15–24: 359 (12.4) 74.2 Not reported New smear-positive TB 0
25–34: 920 (31.7)
35–44: 867 (29.9)
45–54: 399 (13.8)
55–64: 208 (7.2)
o65: 148 (5.1)
COX [27] Not reported Not reported Not reported Smear-positive pulmonary TB 45.3
MATTHYS [15] 29 (16–66) 100 0 Culture-positive TB patients 73
TB: tuberculosis.
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the information collected for this review is mainly from studies
that did not assess our research question we feel that the risk
for publication bias is low, and so downgrading for publication
bias was also not considered necessary. The effect identified in
the meta-analysis is large (RR 26.7), therefore, we believe that
the quality of the evidence should be upgraded by one level,
from ‘‘low’’ to ‘‘moderate’’. No plausible confounding factor
that would change the effect was identified. Also, there was
no dose–response gradient. The overall quality of the evidence
as assessed by the GRADE approach is, therefore, moderate.
This means that we are moderately confident in the effect
estimate, and that the true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is
substantially different.
DISCUSSION
In this review we identified four studies that provided
information for estimating the risk of developing MDR-TB
after the use of a TB regimen that was inappropriate for a
patient, considering the drug resistance pattern of the
M. tuberculosis strain. Only two studies could be used for the
meta-analysis. These two studies showed that the risk of
developing MDR-TB was increased 27-fold in patients who
were prescribed an inappropriate treatment regimen. This
finding supports the general opinion that inadequate treatment
is a risk factor for the development of drug-resistant TB and
MDR-TB.
We chose to include only high quality studies in our review.
Studies had to provide information about drug resistance in
the initial and the recurrent episode, genotyping information
of the TB strain in both episodes and information about
individual TB treatment regimens. We did come across studies
TABLE 5 Risk of bias assessment using the Newcastle–
Ottawa Scale star template
# for cohort studies
First author [ref.] Selection Comparability
" Outcome
SONNENBERG [28] **** – ***
QUY [16] **** – **
COX [27] **** – *
MATTHYS [15] *** – ***
#: a study can be awarded a maximum of one star for each numbered item
within the ‘‘selection’’ and ‘‘outcome’’ category and a maximum of two stars can
be given for ‘‘comparability’’. For the ‘‘selection’’ category a star is awarded if
the exposed cohort is representative; if the unexposed cohort is drawn from the
same community as the exposed cohort; if exposure was ascertained by secure
record or by a structured interview; and if it was demonstrated that outcome of
interest was not present at the start of the study. For ‘‘comparability’’, one star is
awarded if the study controls for the most important factor and another star can
be awarded if the study controls for any additional factor. For ‘‘outcome’’ a star
is awarded if the assessment of the outcome is an independent blind
assessment or by record linkage; if there was a long enough follow-up for the
outcomes to occur; and if there was complete follow-up or if the fact that
subjects were lost to follow-up is unlikely to introduce bias.
": no comparison
was made between individuals receiving appropriate treatment and inappropri-
ate treatment since this was not the interest of the authors.
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exclude re-infection [29, 30]. One study included in our review
provided information on the percentage of MDR-TB in failure
or recurrent cases that is really acquired and not re-infection.
This study by MATTHYS et al. [15] showed that more than 60%
(nine out of 14) of new MDR-TB in failure cases could be
attributed to re-infection. The study was conducted in a
penitentiary hospital in central Siberia (Russia) where the
transmission of TB and MDR-TB is believed to be high, and
thus the chances of re-infection with a MDR-TB strain is also
high. A review on re-infection or relapse not focussing on
MDR-TB showed that the proportion of recurrences due to re-
infection ranged between 0% and 100% [13]. These results are
in themselves not indicative; however, together with the
information from the included studies it shows that an
unknown proportion of the cases with ‘‘acquired’’ MDR-TB
in studies not performing genotyping are due to re-infection. It
is, therefore, essential to have genotyping information to assess
whether new MDR-TB is truly acquired or due to re-infection.
There are several aspects that need to be considered when
interpreting DNA fingerprinting results: 1) changes in the
insertion sequence pattern due to recombination events,
2) heterogeneity of the fingerprinting patterns in a given area,
and 3) mixed infections. Although IS6110 fingerprint patterns
of M. tuberculosis isolates have a high degree of stability,
changes in insertion sequence patterns have been identified,
especially when the time interval between obtaining the
isolates increased [31, 32]. Thus, two strains may be wrongly
identified as different. This provides an underestimation of the
number of strains that acquire drug resistance.
In areas shown to have a low heterogeneity in fingerprinting
patterns [33, 34], patients have a higher chance of becoming re-
infected with an identical strain. If the strain that causes
re-infection is resistant to TB drugs this may wrongly lead to
the conclusion that the patient acquired drug resistance. Also,
strains with a low number of IS6110 copies (five copies or less)
cannot be differentiated between; as the level of discrimination
is low, a strain with a low copy number at failure or recurrence
might be incorrectly identified as the same strain. This would
overestimate the percentage of patients that acquired MDR-TB.
Spoligotyping of such RFLP low copy strains can be used to
further differentiate strains within identical, low-copy RFLP
patterns [35].
The extent of acquired MDR-TB can be overestimated if there
is a low heterogeneity of circulating M. tuberculosis strains. A
study [36], based on the same patient population as that
described by COX et al. [27], identified a high degree of strain
diversity among the patient population. Specifically, 152 (40%)
isolates were in clusters ranging in size from two to 21 isolates;
i.e. 60% of strains were ‘‘unique’’. Given that the level of strain
diversity was relatively high, we believe that the risk that
patients defined as having acquired MDR-TB were in fact re-
infected with an identical strain that was already MDR-TB, is
small. Information about the heterogeneity of strains was not
provided by MATTHYSet al. [15]. In an earlier study in 1999 [37],
strains from the same setting of MATTHYS et al. [15] were
TABLE 6 Data abstracted from the included studies for meta-analysis
#
First author [ref.] Treatment appropriate
based on DST
Non-MDR-TB
patients treated
Patients that failed treatment
and acquired MDR-TB
Patients with recurrence with
acquired MDR-TB
SONNENBERG [28] Yes 294 0
No 29 0
QUY [16] Yes 0 0 0
No 2551 38 10
COX [27] Yes 240 1
No 74 9
MATTHYS [15] Yes 127 0
No 62 5
Data are presented as n. DST: drug-susceptibility testing; MDR: multidrug resistance; TB: tuberculosis.
#: the patients for whom it was unknown whether they acquired
MDR-TB are not included as acquired MDR-TB.
Favours inappropriate use Favours appropriate use
500 10 0.1
Fixed RR IV (95% CI) Fixed RR IV (95% CI)
0.002 1
COX [27]
MATTHYS [15]
Total (95% CI)
Total events
Heterogeneity: Chi-squared=0.02, df=1 (p=0.88); I2=0%
Test for overall effect: Z=3.85 (p=0.0001)
14 1
136 367 100.0 26.68 (5.02–141.70)
9
5
74
62
Study or 
subgroup Events
Inappropriate treatment
Total
1
0
240
127
Events
Appropriate treatment
Total
66.4
33.6
29.19 (3.76–226.62)
22.35 (1.26–397.86)
Weight %
FIGURE 2. Forest and meta-analysis of the two included studies showing the risk ratio (RR) of inappropriate treatment and risk of developing multidrug-resistant
tuberculosis. IV: inverse variance.
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assessed by RFLP, was seen. The authors concluded that there
was ongoing transmission of a few strains within the prison.
This study was performed 8 yrs before the study by MATTHYS
et al. [15] and transmission in prisons might have changed due
to TB control activities in prisons. However, we cannot rule out
the possibility that some cases that were identified with
acquired MDR-TB were actually due to re-infection with an
MDR strain with the same RFLP pattern. If this is the case the
relative risk for developing acquired MDR-TB will be lower.
Until recently, evidence of mixed infection in a single host at a
single time-point was infrequently observed, which probably
reflected the insensitivity of DNA fingerprinting methods [38].
More sensitive methods have shown that TB patients in high-
incidence settings often have different M. tuberculosis strains in
the same sputum specimen [39, 40]. Patients with mixed
infection may thus wrongly be diagnosed with acquired drug
resistance [41]. Newer genotyping methods have since
become available that increase the discriminatory power of
strain genotyping [42], including whole genome typing of
M. tuberculosis [43]. Use of these methods for studying
acquired drug resistance might resolve some of the challenges
discussed previously.
A further consideration, in assessing the acquisition of drug
resistance, is that DST results must be interpreted with caution.
A round of proficiency testing by the supranational TB
reference laboratories showed that DST for rifampicin pre-
sented difficulties in correctly identifying resistance in these
top level laboratories [44]. Also, results for ethambutol and
streptomycin were poor. The studies included in our review
used WHO recommended DST methods. Two studies had all
DST testing performed by a supranational reference laboratory
[15, 27], and one sent a random sample for quality assurance to
a supranational reference laboratory [16]; no discordance was
observed for isoniazid and rifampicin. The study in South
Africa had all testing performed by Lancet Laboratories in
Johannesburg [28].
A limitation of cohort studies for assessing the incidence of
acquired drug resistance is that a number of included patients
in the cohort may die. The cause of death could be the
acquisition of MDR-TB and thus non-response to treatment.
The difficulty in collecting samples from deceased patients to
assess the acquisition of drug resistance means that these cases
will commonly be missed in cohort studies on acquired drug
resistance, thereby resulting in an underestimation of the
incidence of acquired resistance.
Only quality TB drugs will ensure that patients obtain the
required regimen and the required dosage. Content and
stability of TB drugs have been reported to be substandard
[45, 46] and patients receiving substandard drugs may develop
drug resistance even when prescribed an adequate regimen.
The drugs used in the study of MATTHYS et al. [15] were
procured outside Russia and had certificates that guaranteed
their quality. The other included studies did not provide
information about the quality of the drugs.
Inadequate adherence to treatment can also be a form of
inappropriate treatment and thus a risk factor for acquiring
MDR-TB. Furthermore, full adherence to treatment is essential
to ensure the patient is cured. Adherence to treatment was not
used as a criterion in this review for appropriate treatment and
risk of acquired MDR-TB; however, all included studies
mentioned how adherence to treatment was supported. All
indicated that directly observed treatment was provided. QUY
et al., [15] MATTHYS et al., [16] and SONNENBERG et al. [28] all
provided treatment under direct observation. In the study by
COX et al. [27] patients were hospitalised during the intensive
phase of treatment (exposure) and received doses during the
continuation phase, which were ostensibly administered under
the direct observation by local healthcare workers.
With regard to the applicability of the evidence, the evidence is
based on the best quality studies available. However, only two
studies could be included in the meta-analysis. If more studies
become available the review and meta-analysis can be
updated.
CONCLUSIONS
This review provides evidence for the general opinion that the
development of MDR-TB can be caused by treatment that is
inadequate, given the drug susceptibility pattern of the
M. tuberculosis strain. The information can be used to advocate
the need for adequate treatment of patients, based on drug
resistance profiles. Few cohort studies provided information
on treatment regimens and drug resistance profiles before
treatment and at failure or recurrence, or genotyping informa-
tion at failure or recurrence. To monitor the development of
acquired drug resistance we suggest that, given sufficient
resources are available, TB treatment cohort studies or
surveillance systems measure both the drug resistance profile
and genotype information before starting treatment and at
failure or recurrence. This would enable future larger studies
to assess the risk of resistance development due to inappropri-
ate treatment.
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